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SUMMARY 
Many Neglected Tropical Diseases (NTDs) have recently been subject of 
increased focus, particularly with relation to high throughput screening (HTS) 
initiatives. These vital endeavours largely rely of two approaches, in vitro target-
directed screening using biochemical assays or cell-based screening which takes 
no account of the target or targets being hit. Despite their successes both of 
these approaches have limitations, for example the production of soluble protein 
and a lack of cellular context or the problems and expense of parasite cell 
culture. In addition both can be challenging to miniaturize for ultra (u)HTS and 
expensive to utilize. Yeast-based systems offer a cost-effective approach to 
study and screen protein targets in a direct-directed manner within a eukaryotic 
cellular context. In this review we examine the utility, and limitations, of yeast 
cell-based, target-directed screening. In particular we focus on the currently 
under-explored possibility of using such formats in uHTS screening campaigns 
for NTDs. 
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INTRODUCTION 
Over the last few decades high throughput screening (HTS) has become one of, 
if not the most important strategy for the discovery of new drug leads. HTS can 
be undertaken on a number of levels, ranging from individual proteins through 
unicellular systems, e.g. yeast, to multicellular organisms such as zebrafish 
embryos and nematode worms. Each has their benefits and in this review we will 
discuss the utility of yeast-based approaches in HTS, with special focus on their 
potential to be used in the search for much needed novel antiparasitics, including 
those for so-called Neglected Tropical Diseases (NTDs) such as leishmaniasis 
and other kinetoplastid infections, Human African Trypanosomiasis (Sleeping 
Sickness) and Chagas Disease (WHO, 2012a). 
 
HIGH THROUGHPUT SCREENING – A BRIEF OVERVIEW 
One of the major technological advances arising from the advent of genomics 
and combinatorial chemistry approaches to drug discovery was the development 
of HTS. This is a process in which large numbers of compounds are rapidly 
(≥100,000 / day) tested for biological activity. In general HTS assay formats can 
be divided into two types, in vitro biochemical and cell-based assays. The former 
are generally simpler and more specific whilst the latter more challenging but 
give greater content and context (An and Tolliday, 2010). 
For automated HTS, in vitro biochemical assays must negate the need for 
substrate-product separation and produce a readily detectable and quantifiable 
signal (fluorescence, radiochemical etc). This requires purified, active and 
soluble protein. In contrast cell-based platforms do not require purified target 
protein and can be engineered to produce a simple, measurable readout of 
cellular processes for HTS (Barberis et al. 2005). Furthermore, in these formats 
the activity of any compound against a specific target is analyzed in a cellular 
context that more closely resembles the in vivo scenario, for example the 
requirement of an inhibitor to cross the plasma membrane and reach an 
intracellular target. Finally, a well controlled cell-based HTS can identify those 
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compounds that are generically cytotoxic or may exhibit problems with stability or 
solubility in vivo. As such, and compared with in vitro biochemical assay 
platforms, cell-based assays have the potential to identify compounds with drug-
like properties which are ready for further development. See Table 1 for a 
summary of the advantages and disadvantages for each approach. 
To replicate physiological conditions as accurately as possible cell-based assays 
should ideally be performed using the target cell of interest, for example 
protozoan pathogens for NTDs or mammalian cells for anticancer agents (Simon 
and Bedalov, 2004). However, protozoan parasites can be both difficult and 
expensive to culture and genetically manipulate compared to model eukaryotes 
(Limenitakis and Soldati-Favre, 2011). Mammalian cells can pose similar 
problems and, in addition, the redundancy of processes can cofound the readout 
of HTS for a specific inhibitor (Barberis et al. 2005). Yeast, 
Schizosaccharomyces pombe and particularly Saccharomyces cerevisiae, have 
been established as simple, tractable, highly characterised model eukaryotes 
(Castrillo and Oliver, 2011). As well as being accessible through a highly 
developed genetic tool kit, yeast are also relatively fast growing in simple, low-
cost (liquid or solid) media with a doubling time of approximately 90 minutes. 
These features make both of these model species ideal candidates to be 
employed in HTS for antifungals (Hughes, 2002). However, many functions of 
yeast, protozoan and human cells are conserved, allowing straightforward, 
orthologous expression, complementation by replacement and functional 
analyses in a simplified system. In addition, processes not found in yeast can be 
constituted in a heterologous cell by taking advantage of these model systems’ 
wide variety of genetic tools (Munder and Hinnen, 1999). Both of these 
approaches have been successfully utilized in drug discovery programmes and 
here we will examine the strengths and limitations of yeast as a screening tool, 
with particular emphasis on their use for NTD drug discovery (Table 1). 
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YEAST AS A SUBSTITUTION PLATFORM 
Many yeast cell-based assay platforms rely on the substitution of an essential 
yeast gene with an orthologue from the system of interest (Fig. 1) to constitute a 
simple growth assay for inhibition. The generation of such hybrid yeast relies on 
the conservation of protein function between distantly related eukaryotes. This 
approach has been widely used in the study of parasite (Bilsland et al. 2011; 
Klein et al. 1997; Sibley et al. 1997) and mammalian proteins (Munder and 
Hinnen, 1999) through the constitution of phenotypic screening assays. One 
recent example involved the development of an HTS assay to identify inhibitors 
of the human acetyl-CoA carboxylase 2 (AAC2) with a view to discovering 
potential agents for the treatment of obesity (Marjanovic et al. 2010). In this 
example, the S. cerevisiae AAC was replaced using homologous recombination 
by orthologous human AAC 1 and 2, as well as by the corresponding wheat and 
protozoan (Toxoplasma gondii) AACs. Selection of complemented yeast cells 
was facilitated by placing the inserted AAC under the control of a GAL10 
promoter, thereby making the yeast galactose-dependent. Following validation 
using known AAC inhibitors these yeast strains, dependent on human AAC1 and 
2, were screened with 34,000 compounds from three libraries in a 96-well plate 
format where growth was monitored by measuring turbidity at 580-620 nm. The 
hit rate of this primary screen varied from 0.02% to 3.5% depending on the library 
source. Some of these were non-selective for AAC2 whilst, importantly, others 
were shown to be generically toxic in a screen employing wild-type yeast. These 
counter screens are vital to maximize target specificity. In addition, Marjanovic et 
al employed a secondary enzymatic screen to further validate the specificity and 
selectivity of their hits and identify a small subset of AAC2 specific inhibitors that 
conform to Lipinski’s rule of five criteria for drug-like characteristics (Lipinski et al. 
2001).  
This simple approach of screening for phenotypic changes in a complemented S. 
cerevisiae strain has also been used to identify a novel human K+ channel 
inhibitor (Zaks-Makhina et al. 2004). An HTS assay was designed where the K+-
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dependent growth phenotype of K+ channel mutants was rescued by mammalian 
Kir2.1 channel expression. In a 96-well plate format, using turbidity as a growth 
measure, Zaks-Makhina and colleagues screened a 10,000 compound library 
selecting those that inhibited Kir2.1 dependent yeast growth at low but not high 
K+. This assay allowed the identification of compounds showing non-specific 
toxicity, as evidenced by inhibition in the presence of both low and high K+. 
Through this process, 42 compounds with inhibition >50% and toxicity <20% 
were selected. As in the example above, a secondary screen was then 
undertaken to analyze specificity for Kir2.1 over other human and plant K+ 
channels. Inhibition of K+ channels by one of the selected compounds was 
demonstrated in mammalian cells and this inhibitor was also shown to confer 
neuroprotection in cultured neuronal cells. This combination of screens, from a 
large primary effort to a neuronal assay via biochemical and cellular assay, 
demonstrated the step-wise process that can be employed for lead identification. 
Starting from a large library, it is possible using a yeast-based approach to 
quickly identify robust, contextualized hits that can then be rapidly triaged using 
other, perhaps more labour-intensive, assays. 
 
YEAST AS A LETHAL EXPRESSION PLATFORM 
Not all mammalian and protozoan proteins and pathways have functional 
equivalents in yeast. However, in some cases heterologous expression of these 
completely foreign proteins in yeast induces measurable phenotypes which can 
be measured in HTS (Munder and Hinnen, 1999; Simon and Bedalov, 2004). For 
example, over expression of influenza virus ion-channel forming protein M2 in S. 
cerevisiae results in growth impairment. Inhibition of M2 rescues this phenotype 
and this positive readout growth assay has been used in a 96-well plate based 
assay to identify a novel inhibitor from a library screen that demonstrated antiviral 
activity in cell culture (Kurtz et al. 1995). 
Similarly, using the fission yeast S. pombe, the pro-apoptotic HIV-1 protein Vpr 
has been formatted into 96- and 384-well yeast-based screens (Benko et al. 
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2010). As for the M2 assay, toxic expression was controlled via an inducible 
promoter and restoration of growth was measured using optical density in a very 
simple ‘mix-and-measure’ primary assay requiring no complicated preparation, 
centrifugation, filtration, or extraction (Benko et al. 2010; Kurtz et al. 1995). 
Significantly, these yeast constructs were also suitable for the necessary 
secondary assays. Initially an agar plate-based, semi-quantitative colony-forming 
test showing dose dependent effects, and subsequently a fluorescence-based 
LIVE/DEAD yeast viability assay was utilized as an indicator of the desired anti-
apoptotic effect. Whilst agar plate-based systems do not easily lend themselves 
to high volume applications, the fluorometric readout of the latter assay could 
potentially be formatted for HTS. By the cut off criteria set by the research team, 
a screen of a small 2000 compound library gave a single hit from the primary 
screen. This drug, benfotiamine, showed a dose response effect and suppressed 
apoptosis in secondary assays, however further analyses are required to fully 
verify the mode of action (Benko et al. 2010). 
The two examples above were studies focused on the discovery of antiviral 
agents against influenza and HIV respectively. However, the majority of 
screening programmes employing yeast-based approaches have been directed 
at human cellular processes (Barberis et al. 2005; Simon and Bedalov, 2004). 
For example phosphatidylinositol 3-kinase (PI3K) pathway mediates cell 
transduction via the generation of the second messenger phosphatidyl-3,4,5-
trisphosphate and inappropriate activation of this pathway is associated with 
oncogenesis (Wu, 2010). Overexpression of PI3K in S. cerevisiae is lethal and, 
as in the viral examples above, this phenotype was used in an agar plate-based 
rescue screen – this time against 9600 natural product extracts (Fernandez-
Acero et al. 2012). Amongst the barriers to the deployment of yeast in HTS is the 
presence of extremely effective drug efflux systems (Barberis et al. 2005). 
Interestingly Fernandez-Acero and colleagues exploited the genetic tractability of 
yeast to improve the sensitivity of their platform. Deletion of the efflux pump Snq2 
enhanced sensitivity 2-fold in the semi-quantitative assay developed, 
demonstrating the potential of engineering yeast to optimize their use in HTS. 
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Furthermore, Fernandez-Acero et al found that non-lethal disruption of the 
plasma membrane through the addition of small quantities (0.0003%) of sodium 
dodecyl sulphate to the media had a similar ‘sensitizing’ effect, although the 
general utility of such chemical approaches in HTS is unclear.  
Clearly, the measurement of growth on agar plates (Fernandez-Acero et al. 
2012) can only be semi-quantitative and most studies measure turbidity of liquid 
culture in a microtitre plate via optical density. For example rescue of toxic 
expression of human p38α, a kinase with major implications in oncogenesis and 
inflammatory disease, in S. cerevisae was quantified in this way and used in a 
phenotypic rescue HTS to identify 2 compounds, from a library of 40,000, that 
restored growth. Both of these inhibited activity in in vitro and in mammalian cell 
secondary assays (Friedmann et al. 2006). 
In a rather different approach a heat sensitive yeast mutant (fmc1Δ) has been 
used to screen 12,000 compounds for entities that reversed an inability to grow 
with glycerol as the sole carbon source. This relates to a defect in the ATP 
synthase assembly and as such serves as an effective model for certain 
mitochondrial diseases e.g. NARP (neuropathy, ataxia and retinitis pigmentosa) 
(Couplan et al. 2011). In their assay platform Couplan and colleagues used filters 
spotted with each compound to identify those that induced an enhanced halo of 
growth when placed on solid glycerol medium spread with the yeast strain of 
interest. This approach was modeled on one developed for yeast-based 
screening for inhibitors of prion toxicity (Bach et al. 2003; Bach et al. 2006). 
However, here the researchers utilized a yeast prion model which, due to a stop 
codon read through phenotype, are able to metabolize exogenous adenine. 
Inhibitors of the formation of the toxic prion protein (PrPSc, insoluble Sup35p in 
yeast) lead to the yeast being unable to metabolize adenine and the colonies on 
the solid media obtained a dark red colour distinguishable from the usual white 
appearance. Again, these approaches, monitoring growth on solid-media, appear 
unlikely to lend themselves to true (ultra) HTS for 100s of thousands of 
compounds.  
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These data (Bach et al. 2003; Bach et al. 2006; Couplan et al. 2011) show that 
for some processes, the conservation between yeast and the target organism is 
close enough to allow direct, informative screening against the model system. In 
addition, it is important to recognize that in all these cases of phenotypic rescue 
the possibility of generically toxic false positives is removed greatly simplifying 
the generation and interpretation of data.  
 
YEAST AS A TRANSACTIVATION PLATFORM   
In all cases discussed so far the HTS read out has relied on phenotypic changes, 
either positive or negative growth, directly resulting from inhibition of a specific 
function mediated by a specific protein. However, the genetic tractability of yeast 
allows cells to be engineered so that the HTS readout is the result of 
transactivation of another process. A good, and extensive, example of this is 
provided by the work of the Hoffman laboratory (Boston College) towards the 
identification of inhibitors of mammalian phosphodiesterases (PDEs) (Demirbas 
et al. 2011). Tissue specific PDEs (in mammals approximately 100 isoforms 
encoded by 21 genes) convert cAMP to 5’AMP and cGMP to 5’GMP, serving to 
regulate the levels of these cyclic secondary messengers which influence a wide 
variety of cellular processes in a tissue specific manner. Selective inhibition of 
PDE enzymes has therapeutic potential for a wide range of diseases (Bender 
and Beavo, 2006; Conti and Beavo, 2007). The basis of the assay designed by 
Hoffman and colleagues is fission yeast, S. pombe, which unlike S. cerevisiae 
can tolerate loss of function mutations of its adenylyl cyclase. These yeast-based 
assay lines were also engineered to controllably express the selectable marker 
ura4. In the absence of adenylyl cyclase and PDE (Csg2 in yeast) exogenous 
cAMP or cGMP activates PKA and ura4 expression is repressed. Under these 
conditions the yeast are able to grow in the presence of 5-fluoroorotic acid 
(5FOA), which is converted to toxic fluoroorotidine monophosphate in the 
presence of URA4 (Fig. 2). However, expression of either yeast PDE (Csg2) or 
heterologous (e.g. human) PDE leads to the conversion of cAMP to 5’AMP or 
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cGMP to 5’GMP, expression from ura4 and 5FOA sensitivity (5FOAS) (Demirbas 
et al. 2011). This system provides an elegant positive selection platform for PDE 
inhibitors, with inhibition of the enzyme conferring 5FOA resistance (5FOAR) on 
the yeast (Fig. 2). This robust assay system, measuring growth by optical density 
in 384-well plates, has been utilized for HTS of compound libraries against 
several human PDEs. A small subset of compounds (3120, including known PDE 
inhibitors) were screened against human PDE2A, PDE4A and PDE4B, and yeast 
Cgs2 (Ivey et al. 2008). In addition to the known inhibitor controls, several 
specific inhibitors were identified, with the assay having a hit rate of 0.8% to 
3.2%. In a secondary screen a subset of these compounds demonstrated the 
ability to raise the level of cellular cAMP, indicating PDE inhibition (Ivey et al. 
2008). PDE7 has been similarly screened, this time with a library of nearly 
50,000 compounds (Alaamery et al. 2010). This HTS identified two compound 
classes conferring the highest growth, i.e. PDE inhibition and rescue. A subset of 
these demonstrated PDE7 selectivity and activity in an in vitro secondary screen. 
Importantly, one of these potently suppressed TNFα release by LPS-stimulated 
model macrophage cells indicating a possible anti-inflammatory effect of PDE7 
inhibition (Alaamery et al. 2010). More recently, a 200,000 member compound 
collection was screened against PDE11 expressing yeast (Ceyhan et al. 2012). 
Using data from previous screening campaigns to remove non-specific hits, 39 
compounds were selected for secondary selectivity and dose dependency 
assays; this identified four compounds as potent and highly selective. One of 
these compounds induced high cAMP levels in a mammalian cell-based assay 
and the same compound induced cortisol production (associated with PDE11 
inactivation) in these cells (Ceyhan et al. 2012). Collectively these studies 
present the largest body of work in the literature describing the use of yeast for 
cell-based, target-directed HTS. Furthermore, other studies have employed a 
similar transactivation platform for HTS. Like Hoffman and colleagues, Grozinger 
et al utilized 5FOAS / 5FOAR selection in a screen for inhibitors of ura3 repression 
by the yeast transcriptional repressor Sir2p, a NAD-dependent deactylase. 
However this study used a negative growth screen in which hits from a small 
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1600 compound collection were scored for their ability to confer 5FOAS, i.e. 
inhibit Sir2p, to S. cerevisiae (Grozinger et al. 2001). General cytotoxicity was 
established against yeast grown without FOA and three compounds were further 
assessed for their ability to selectively inhibit the activity of the human 
orthologue, SIRT2.  
A direct screen for inhibitors of mammalian protein function, using an alternative 
transactivation system, is illustrated by a HTS against human β-secretase 
expressed in S. cerevisiae (Middendorp et al. 2004). This enzyme drives the 
production of the Αβ peptides thought to be associated with Alzheimer’s disease 
and therefore inhibitors could have significant medicinal value. Screening was 
undertaken using a modified yeast strain in which invertase is engineered to only 
be active and released upon cleavage by human β-secretase (an enzyme not 
found in yeast). Without intervention the yeast cannot grow in histidine-depleted 
media with sucrose, as released invertase cleaves sucrose to form glucose 
which represses the expression of a HIS3 selectable marker. However, on β-
secretase inhibition invertase is not released and the cells are rescued in this 
positive screen (Middendorp et al. 2004). Similarly, again in brewers’ yeast, an 
orphan human G-protein coupled receptor (GPCR) was coupled to histidine 
prototrophy. In this case, stimulation of the GPCR facilitated growth in the 
absence of histidine and a positive readout assay was then formatted to identify 
peptide agonists (Klein et al. 1997).  
Two-hybrid screens also fall into this transactivator class of platform, and 
although they have not been extensively employed in HTS, they have been used 
to identify modulators of protein-protein interactions. The interaction of human 
calcium channel subunits α1B and β3 has been coupled to a marker conferring 
cycloheximide sensitivity (Young et al. 1998). A screen of >150,000 compounds 
identified 10 compounds that rescued growth of the α1B and β3 strain, but not a 
control strain in the presence of cycloheximide. These were subsequently 
assessed for their ability to modulate calcium channels. Whilst in this screen of 
calcium channels Young et al monitored growth on agar plates, all the other 
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screens using transactivation systems discussed here employed turbidity 
measurements which is a more quantitative approach that allows the robustness 
of the assay to be assessed accurately as discussed below.  
 
YEAST-BASED SCREENING FOR ANTIPARASITICS 
NTDs are caused by a diverse group of 17 infections, 11 of which are caused by 
protozoan or helminth parasites (WHO, 2012a). They are almost exclusively 
diseases of poverty, affecting a staggering 2.7 billion people who live on less 
than $2/day. NTDs are endemic in tropical and sub-tropical regions of the 
developing world, with Africa, Asia and Latin America carrying 90% of the 
disease burden. In the absence of vaccines many of these parasitic diseases 
lack adequate therapeutic regimes, with many of the few available drugs being 
not widely available, costly, and/or exhibiting unacceptable side effects (WHO, 
2012a). Recently, public-private initiatives have lead to increased focus on NTDs 
and a renewed drive to discover new and better therapeutic agents (Allarakhia 
and Ajuwon, 2012; WHO, 2012b). Both in vitro biochemical (Frearson et al. 2010) 
and parasite cell-based (Siqueira-Neto et al. 2012) screening technologies have 
been deployed in this effort. However, both have limitations and cost implications 
as discussed above (Table 1). To overcome these and accelerate the process of 
NTD drug discovery the use of yeast as a screening vehicle may become more 
prevalent. Examples of all the strategies described above are possible although 
all the reported approaches, described below, rely on using yeast as a 
substitution platform. 
In 1997 Klein et al described an HTS assay utilizing a S. cerevisae ornithine 
decarboxylase (ODC) mutant complemented by expression of ODC from the 
nematode worm Haemonchus contortus, a major parasite of ruminants (Klein et 
al. 1997). ODC is a key regulatory enzyme in the biosynthesis of polyamines 
(PA) in eukaryotes, which has been established as an antiprotozoal target with 
the inhibitor difluoromethylorthine (DFMO; eflornithine) a key treatment for 
Human African Trypanosomiasis (Heby et al. 2007). In contrast to the ODC 
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mutant parent strain, an H. contortus ODC complemented yeast line was able to 
grow in the absence of exogenous PA (Klein et al. 1997). This complemented 
yeast cell line was utilized in a 96-well plate-based assay to screen 90,000 
compounds for their ability to inhibit cell growth (quantified using Alamar Blue) in 
the absence of PA. The approximate 1% hits of this primary screen were 
subsequently retested against the same yeast line grown in the presence of PA, 
when ODC is redundant. This counter screen identified those compounds that 
demonstrated general toxicity leaving a single, target specific hit, stilbamidine 
isethionate. However, this compound showed no activity against the helminth 
ODC in vitro and was hypothesized to inhibit yeast S-adenosylmethionine 
decarboxylase (SAMdc), an enzyme required for spermidine and spermine 
synthesis (Klein et al. 1997). This exemplifies, in this simple eukaryotic model, 
the issue of process redundancy discussed above in relation to more complex 
mammalian cell-based screening. 
Until very recently this was the only published yeast-based HTS for 
antiparasitics, although the potential of these platforms for this purpose has been 
recognized with respect to the protozoal acetyl-CoA carboxylase (Marjanovic et 
al. 2010). However, drug sensitivity yeast mutants have been used to identify the 
primary targets and possible toxic effects of the antimalarials quinine (Khozoie et 
al. 2009), St. John’s Wort (McCue and Phang, 2008) and artemisinin (Li et al. 
2005). In addition, the use of S. cerevisiae as a vehicle for antiprotozoal drug 
discovery has been explored with drug targets from the causative agent of 
malaria Plasmodium falciparum. P. falciparum dihydrofolate reductase (DHFR, 
essential for thymidine, histidine and methionine synthesis) and topoisomerase II 
(decatenation of DNA) have both been used to complement corresponding yeast 
mutants (Sibley et al. 1997). This work was recently further developed by 
Bilsland et al in an exploration of mutant S. cerevisiae complemented with DHFR 
from P. falciparum, P. vivax, Leishmania major (a causative agent of 
leishmaniasis), Trypanosoma brucei brucei (an animal pathogen serving as a 
model for Human African Trypanosomiasis), T. cruzi (Chagas Disease),  
Schistosoma mansoni (schistosomiasis) and Homo sapiens (Bilsland et al. 
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2011). In an agar plate-based assay the well characterized antimalarial 
pyrimethamine was able to inhibit the growth of yeast complemented with 
Plasmodium DHFR as expected. Notably, complementation with drug-resistant 
Plasmodium DHFR conferred pyrimethamine resistance thus confirming target 
specificity. All of the other complemented strains demonstrated lower sensitivity 
to the drug, although sensitivity became more evident on suppression of DHFR 
expression. Deletion of the major multidrug export pump encoded by PDR5 also 
increased the sensitivity of the T. brucei DHFR strain to pyrimethamine. This 
platform was further developed and utilized in HTS applications for specific 
inhibitors of parasite DHFR, N-­‐myristoyltransferase (NMT) and phosphoglycerate 
kinase (PGK) (Bilsland et al. 2013). Here DHFR, NMT and PGK mutant S. 
cerevisiae were complemented by expression of the fluorescently-tagged 
parasite orthologues. By using fluorescent protein tags with non-overlapping 
spectra the assay was multiplexed, allowing for multiple readings to be taken 
from a single well. This platform was then used, utilizing an automated 384-well 
protocol, to screen the Maybridge Hitfinder Library (14,400 chemically diverse 
compounds) to identify parasite specific hits (i.e. those not affecting yeast 
dependent on expression of the human orthologue). Of the 36 specific hits 
identified against the kinetoplastid protozoan enzymes (T. b. brucei, T. cruzi, L. 
major), 18 were cytotoxic for T. b. brucei in cell culture.  
S. cerevisiae have also been employed in the study of the Leishmania inositol 
phosphorylceramide (IPC) synthase, a putative antiprotozoal drug target (Denny 
et al. 2006; Mina et al. 2009). Exploiting public-private partnership we have 
developed and deployed a robust yeast-based, 1536-well formatted assay for 
ultra (u)HTS (Norcliffe et al. unpublished). The uHTS campaign involved the 
screening of the GSK compound collection, 1.8 million compounds, and is, to the 
best of our knowledge, the largest yeast-based screen reported to date. IPC 
synthase is a membrane-bound enzyme with six trans-membrane domains that 
drives the formation of IPC, a non-mammalian phosphosphingolipid and a major 
component of the parasite plasma membrane. Preliminary studies had led to the 
development of a 96-well plate-based enzyme assay system that was utilized to 
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define the mode of action of the Leishmania IPC synthase (Mina et al. 2010) and 
investigate its substrate binding requirements (Mina et al. 2011). However, the 
complexity of this microsomal assay, with a requirement to separate lipid 
substrate and product, precluded its employment as a true HTS platform. To 
facilitate a high volume approach a yeast-based assay was formatted in S. 
cerevisiae, utilizing the ability of the protozoan enzyme to complement for the 
absence of its functional orthologue AUR1p (Nagiec et al. 1997), in which growth 
could be coupled with a fluorometric output enabling on and off target effects to 
be discriminated. The primary screen was successfully executed with, following 
initial dose response secondary assays, > 500 potent and selective hits identified 
(0.03% hit rate). Secondary screening is currently underway and the full results 
of this yeast-based uHTS will be reported in due course. 
These results demonstrated the ability to engineer yeast to optimize a robust 
assay platform and exemplify the utility of this model eukaryote as a vehicle for 
drug analyses and screening in NTDs, for example with respect to the 
kinetoplastid protozoa. Consequently, the potential for yeast-based screens to 
assist in the search for new solutions for NTDs is now well established. Whilst 
only the substitution approach, in which orthologous enzymes are explored, has 
been used to date it can only be expected that, with time, the other approaches 
will become viable. Whilst the development of lethal expression systems for NTD 
pathogen target screening probably requires further functional analyses of 
protein function in many of these organisms, the application of transactivation 
approaches looks much closer. For example, co-expression of human 
cytomegalovirus (HCMV) protease with an engineered Trp1p enzyme has been 
used to identify HCMC protease inhibitors that prevent cleavage of Trp1p to 
stimulate growth in media lacking trytophan (Cottier et al. 2006). However, these 
transactivation technologies could readily to applied to parasite systems provided 
the knowledge base is there to indicate protein target function, interactions etc. In 
this respect, building directly on the work of the Hofmann group described above, 
protozoan PDE orthologues are widely characterized and shown to be essential, 
putative drug targets in several pathogenic species (Seebeck et al. 2011). 
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Consequently there is every prospect of formatting these into the various assay 
platforms discussed to facilitate the search for novel, selective inhibitors which 
will act as lead compounds for antiparasitic drug discovery.  
 
DSICUSSION AND CONCLUSIONS 
As evidenced by the results summarized above, yeast based screening 
methodologies offer considerable benefits for HTS (Table 1). Cell-based, yet 
target-directed assays can be readily developed and their eukaryotic nature 
confers a relevant cellular context not available in highly tractable bacterial 
systems. Where determined and stated the Z-factors of yeast cell-based, target-
directed screens lie well above the generally accepted threshold (0.5) for an 
excellent, robust assay (Benko et al. 2010; Demirbas et al. 2011; Fernandez-
Acero et al. 2012). Most of these screens are relatively simple, using “mix and 
measure” approaches with measurement achieved by monitoring yeast growth in 
liquid media via optical density. Higher content readouts are possible using 
colour- or fluorometric responses and these will continue to add value in the 
future (Bilsland et al. 2013). Importantly, miniaturization is possible with a number 
of the assays being run in 384-well plate format (Benko et al. 2010; Demirbas et 
al. 2011; Bilsland et al. 2013), however further miniaturization to a 1536-well 
format is desirable for uHTS. Therefore, as discussed, yeast can serve as a 
cheap, flexible and robust assay platform suitable for miniaturization to facilitate 
HTS and uHTS. Importantly, as outlined above, all yeast-based HTS must 
employ panels of counter screens and secondary assays to rule out off target 
effects. In particular those platforms relying on growth inhibition readouts are 
prone to identify off target hits and the Molecular Mode of Action (MMoA) must 
be corroborated (Marjanovic et al. 2010). 
The ability to specifically screen for target inhibition in a well controlled cellular 
context, whilst reducing the challenge caused from confounding effects due to 
pathway redundancies, is further enhanced by the relatively rapid growth of yeast 
compared with higher eukaryotic cells. As described various assay platforms can 
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be envisaged and the ability to screen ‘hard to purify’ or ‘hard to assay’ proteins 
(e.g. transmembrane enzymes involved in lipid biosynthesis) can be enhanced. 
However, as with all HTS assay platforms, yeast has limitations. Not least the 
ability to constitute or substitute heterologous protein function in another 
organism. In addition, the thick yeast cell wall may serve as a barrier to 
compounds in a screen and highly expressed efflux pumps may exclude these 
(Table 1).  Whilst both of these can reduce the sensitivity of a given assay, it is 
evident that engineering the yeast to lack efflux pumps is a viable strategy to 
increase sensitivity (Bilsland et al. 2011; Fernandez-Acero et al. 2012).  
In summary, it is clear that yeast can serve as a vehicle for HTS of human, viral 
and protozoan or helminth parasite proteins. In particular yeast systems appear 
ideally suited for HTS and much needed drug discovery for the parasites that 
underlie many of NTDs. Given the robust and reproducible nature of these assay 
systems, and the facility to further engineer yeast strains to provide greater 
sensitivity, the use of such platforms is likely to become more commonplace. 
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 TABLE AND FIGURE LEGENDS 
 
Table 1 
The advantages and disadvantages of the screening platforms employed for 
antiparasitic drug discovery. 
 
Figure 1 
Substitution platform. In these cases the yeast open reading frame (black) is 
replaced with a foreign open reading frame (red) encoding an orthologous 
protein. This can be easily achieved by either direct substitution via homologous 
recombination incorporating a selectable marker / inducible promoter (A) or, for 
example, by plasmid shuffle in a knockout yeast line reliant on expression of an 
essential protein from a uracil selectable plasmid (B). In the presence of 5FOA 
the ura marker will be selected against allowing a plasmid encoding a functional 
orthologue of the essential protein to replace it. In both of these cases, for an 
HTS platform to be constructed, the yeast-encoded protein must be essential and 
a functional orthologue must be present in the system of interest. A counter 
screen, for example against wild type yeast or, better, yeast complemented with 
the native protein, is essential to identify off target effects causing generic 
cytotoxicity.  
 
Figure 2 
Transactivation platform. Expression of the fbp1-ura4 reporter in the yeast 
screening strain is repressed by Protein Kinase A, which is activated by the 
addition of cAMP (or cGMP) to the media.  Hydrolysis of cAMP (or cGMP) by 
either yeast or human (or protozoan) PDE allows ura4 expression leading to a 
FOAS growth phenotype (A). PDE inhibition causes cAMP (or cGMP) to 
accumulate repressing ura4 expression leading to a 5FOAR phenotype (B). This 
positive growth readout negates the need for a yeast cytoxicity control as 
compounds inhibiting growth through off target effects will not be rescued by 
PDE inhibition. 
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TABLE 1 
Platform In vitro HTS Cellular HTS 
(parasites) 
Yeast-based HTS 
Advantages Possibility of simple, 
specific and sensitive 
assay system 
Facilitates SAR based 
on molecular 
recognition of the 
target 
 
 
Does not require purified 
target 
Provides specific cellular 
context allowing early 
selection of drug-like 
compounds 
Naïve approach 
challenging all targets at 
once in an unbiased 
manner 
Does not require purified 
target 
Provides axenic 
eukaryotic cellular 
context allowing early 
selection of drug-like 
compounds 
Ease of manipulation and 
speed of growth 
Straightforward genetic 
manipulation for generic 
assay platform 
Ease of discrimination of 
false positive hits 
Low cost of culture 
Disadvantages Requires purified 
target, limiting assay of 
hard to purify/assay 
targets such as 
transmembrane 
enzymes 
Expensive due to 
necessity for protein 
purification etc 
Requirement for 
suitable substrates 
Relatively insensitive 
due to drug pumps and 
membrane barriers 
Expensive or inability to 
culture relevant lifecycle 
stages 
Limitations in genetic 
manipulation for assay 
platform 
Assays currently rely on 
non-target specific, 
phenotypic output 
SAR is not assisted by 
target knowledge. 
Target deconvolution is 
approached a posteriori 
Relatively insensitive due 
to drug pumps, 
membrane barriers and 
the thick cell wall 
Reliant on the ability of 
an heterologous protein 
to be functional in an 
axenic system 
Target protein is tested in 
a non-native cellular 
milieu 
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FIGURE 1 
 
 
 
FIGURE 2 
 
